Samsung BioLogics’ USD2.3 Billion Acquisition of Samsung Bioepis

Giulia Di Palma Europe Legal Chronicle
Tagged:

Linklaters advised Samsung BioLogics on the deal.Samsung BioLogics, a Korean company active in the development and manufacturing of biopharmaceutical products worldwide, in its agreement with Biogen…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:
Giulia Di Palma

Author: Giulia Di Palma

…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here